The hypoxia-inducible transcription factor (HIF)-1α inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here, we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with other
are also deregulated in cancer further validates HIF-1α as a promising anticancer target. Additionally, the fact that the modulation of a number of unrelated molecular targets ultimately results in HIF-1α inhibition through various mechanisms, including HIF-1α synthesis, degradation, or transactivation, underscores the significance of HIF-1α as a critical signaling hub, regulating cellular responses to a wide variety of stimuli. It is noteworthy that a large number of HIF-1α inhibitors appear to act at the level of translation. This highlights the significance of translation as a major pathway maintaining HIF-1α levels during hypoxia at a time when global protein translation is attenuated. However, the precise mechanism allowing for preferential HIF-1α translation during hypoxia remains unclear.
First generation drugs have shown that HIF-1α inhibition may provide an effective antitumor strategy. The main antitumor effect of HIF-1α inhibition appears to be through an antiangiogenic effect mediated by the downregulation of HIF-1α downstream targets such as vascular endothelial growth factor (VEGF). As a result, the antitumor effects of HIF-1α inhibitors are mostly manifested in vivo, where angiogenesis is critical for continued tumor growth (3). Narita and colleagues show that KC7F2 is cytotoxic to cancer cells in normoxia when cells do not normally express HIF-1α, and that KC7F2 cytotoxicity is potentiated by hypoxia. This suggests that although HIF-1α inhibition during hypoxia may contribute to KC7F2 cytotoxicity, the cytotoxicity under normoxia likely occurs through a separate mechanism. Further characterization of KC7F2 will show whether its HIF-1α-independent toxicity could be a potential source of unwanted side effects. It should be noted that topotecan, a topoisomerase I inhibitor that inhibits HIF-1α translation, causes cytotoxicity by a mechanism dependent upon DNA replication-mediated DNA damage yet decreases HIF-1α protein levels independently of DNA damage, suggesting a mechanism of HIF-1α inhibition distinct from the one responsible for the cytotoxic effects (4). Indeed, many HIF-1α inhibitors have been shown to have multiple targets that may be important for their antitumor or anti-HIF-1α activity. Additionally, many of the HIF-1α inhibitors currently in clinical trials have some other mechanisms of action that could also rationally account for their activity, such as the inhibition of targets critical for functions including cell signaling, DNA replication, and cell division. For these agents, it may be difficult to determine the extent that HIF-1α inhibition plays in antitumor activity. Nevertheless, some HIF-1α inhibitors achieve their potency by inhibiting HIF-1α at multiple levels. The guanylyl cyclase activator YC-1 inhibits HIF-1α by promoting HIF-1α degradation, inhibiting HIF-1α synthesis, and disrupting its transcriptional activity by interfering with the HIF-1α/p300 interaction (5). PX-478, a HIF-1α inhibitor currently in a Phase I clinical trial, inhibits HIF-1α by decreasing HIF-1α translation and, to a lesser extent, transcription and deubiquitination of HIF-1α (6). It is interesting that KC7F2 is a disulfide compound similar to PX-12, a dual thioredoxin and HIF-1α inhibitor that is also in early clinical trials (7) . Narita and colleagues propose that KC7F2 inhibits HIF-1α translation by reducing the phosphorylation of the translational repressor eIF4E binding protein (4E-BP1) and the ribosomal kinase S6K, thus preventing initiation of translation. As HIF-1α is one of the few proteins whose translation is maintained during hypoxia, this could be a mechanism by which KC7F2 achieves selective inhibition of HIF-1α. However, it should be noted that both 4E-BP1 and S6K, downstream targets of the mTOR pathway, are generally believed to already be inhibited in hypoxia as a means to reduce global protein translation (8) . It will be interesting to see whether KC7F2 inhibits phosphorylation of these proteins in normoxia or whether the effect of KC7F2 on the translational machinery is hypoxia dependent.
Ultimately, although many agents have been shown to inhibit HIF-1α in cells, only a few have been shown to inhibit HIF-1α in vivo and to have significant antitumor activity. The higher selectivity of KC7F2 for cancer versus normal cells and its increased cytotoxicity toward these cells in hypoxia versus normoxia is promising. Further work is needed to show whether KC7F2 will live up to its potential in vivo.
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